MNTA  Momenta Pharmaceuticals Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

-0.20 (-1.67%)

Stability Price

Overvalued by 97.42%

Company Metrics

  • 13.83 P/E
  • 13.66 P/S
  • 2.74 P/B
  • -2.126 EPS
  • -146.29% Cash ROIC
  • 11.20 Cash Ratio
  • 0 / 0% Dividend
  • 493,292.00 Avg. Vol.
  • 607.5M Market Cap.

Company Description

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for th...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Momenta Pharmaceuticals Announces Abbreviated New Drug Application for ...
MarketWatch - 9 hours ago
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs and is headquartered in Cambridge, MA.
Mylan, Momenta, Sandoz join assault on Teva's new-and-improved Copaxone - FiercePharma
Momenta Pharmaceuticals President Craig A. Wheeler Sells 2209 Shares (MNTA)
WKRB News - Aug 27, 2014
Momenta Pharmaceuticals (NASDAQ:MNTA) last released its earnings data on Thursday, July 31st. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by $0.05.
Momenta Pharmaceuticals Heading For A Repeat
Seeking Alpha (registration) - Aug 5, 2014
On the cusp of another big biosimilar launch, Momenta would like to avoid another rapid decline. The company's deal with Novartis concerning generic Copaxone -- Teva's (NYSE:TEVA) popular multiple sclerosis therapy -- has a couple features that could ...
Insider Selling: Craig A. Wheeler Unloads 2209 Shares of Momenta ...
Ticker Report - Aug 26, 2014
Momenta Pharmaceuticals (NASDAQ:MNTA) traded up 1.20% during mid-day trading on Tuesday, hitting $11.82. 245,624 shares of the company's stock traded hands. Momenta Pharmaceuticals has a one year low of $9.85 and a one year high of $19.90.
Technical Roundup on Biotech Stocks -- Medivation, Ironwood Pharma ...
Wall Street Journal - Aug 12, 2014
Shares in Momenta Pharmaceuticals Inc. have advanced 3.36% in the previous three trading sessions. However, the company's shares are down 2.90% in the last one month and 35.58% on YTD basis.
Momenta Pharmaceuticals Reports Second Quarter 2014 Financial Results
MarketWatch - Jul 31, 2014
Momenta Pharmaceuticals, Inc. MNTA, +3.00% today reported its financial results for the second quarter ended June 30, 2014.
Pharma Stock Updates: AstraZeneca plc (ADR) (NYSE:AZN), Momenta ... -
Momenta Pharmaceuticals President Sells $25293 in Stock (MNTA)
sleekmoney - 10 hours ago
The company had revenue of $11.00 million for the quarter, compared to the consensus estimate of $11.22 million. During the same quarter last year, the company posted ($0.57) earnings per share. Momenta Pharmaceuticals's revenue was up 151.1% ...
Active Stocks to Watch : ARM Holdings plc (NASDAQ:ARMH), Twitter (NYSE ... - Crazy Joys
Stocks in the News: FuelCell Energy Inc (NASDAQ:FCEL), Lululemon Athletica ... - Financial Wired (registration)
Insider Selling: Momenta Pharmaceuticals Director Sells 3721 Shares of Stock ...
WKRB News - Aug 15, 2014
Momenta Pharmaceuticals (NASDAQ:MNTA) traded down 0.26% on Friday, hitting $11.65. 188,459 shares of the company's stock traded hands. Momenta Pharmaceuticals has a 52-week low of $9.85 and a 52-week high of $19.90. The stock's 50-day moving ...
Insider Selling: Bennett M. Shapiro Sells 3722 Shares of Momenta ...
WKRB News - Aug 20, 2014
Momenta Pharmaceuticals logo Momenta Pharmaceuticals (NASDAQ:MNTA) Director Bennett M. Shapiro sold 3,722 shares of the company's stock on the open market in a transaction dated Friday, August 15th. The stock was sold at an average price of ...
Traders Are Watching : Exa Corporation (NASDAQ:EXA), Microchip Technology ... - WallStreet Scope
Momenta Pharmaceuticals Director Sells $44652 in Stock (MNTA)
Mideast Time - Aug 18, 2014
Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) traded up 0.43% during mid-day trading on Friday, hitting $11.73. 334,832 shares of the company's stock traded hands. Momenta Pharmaceuticals has a one year low of $9.85 and a one year high of ...
Insider Selling: Bennett M. Shapiro Unloads 3721 Shares of Momenta ... - Ticker Report
Momenta Pharmaceuticals Director Sells $44664 in Stock (MNTA) - Watch List News (press release)